N-butyl-isofagomine | 204992-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-butyl-isofagomine
• 英文别名: N-butylisofagomine；(3R,4R,5R)-1-butyl-5-(hydroxymethyl)piperidine-3,4-diol；(3R,4R,5R)-1-butyl-5-hydroxymethyl-3,4-piperidinediol；3,4-Piperidinediol, 1-butyl-5-(hydroxymethyl)-, (3R,4R,5R)-
• CAS: 204992-71-2
• 化学式: C₁₀H₂₁NO₃
• 分子量: 203.282
• InChiKey: MNMGUPFDAVSAED-OPRDCNLKSA-N

物化性质

• 沸点：
  352.2±11.0 °C(Predicted)
• 密度：
  1.125±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (3aS,4R,7S,7aS)-4-(benzyloxy)-2,2-dimethyltetrahydro-4H-[1,3]dioxolo[4,5-c]pyran-7-yl trifluoromethanesulfonate 在 palladium dihydroxide 盐酸 、 18-冠醚-6 、 4 A molecular sieve 、 氢气 、 sodium cyanoborohydride 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 N-butyl-isofagomine
  参考文献：
  名称：

  高效强力β-葡萄糖脑苷脂酶抑制剂的合理设计和合成。

  摘要：

  DOI：

  10.1002/anie.200502662

文献信息

• 1-<i>N</i>-Iminosugars:  Potent and Selective Inhibitors of β-Glycosidases
  作者：Yoshitaka Ichikawa、Yasuhiro Igarashi、Mie Ichikawa、Yoshitomo Suhara

  DOI：10.1021/ja973443k

  日期：1998.4.1

  are both highly potent and selective for β-glycosidases. Designed on the basis of the transition-state model of the β-glucosidase reaction, these iminosugar inhibitors differ from the currently available inhibitors in possessing a nitrogen atom at the anomeric position of the pyranose ring, thereby generating a positive charge on the anomeric position rather than on the ring oxygen of the sugar. Their

  合成了一系列 1-N-亚氨基糖，以满足对高效且对 β-糖苷酶具有选择性的糖苷酶抑制剂的需求。基于β-葡萄糖苷酶反应的过渡态模型设计，这些亚氨基糖抑制剂与目前可用的抑制剂的不同之处在于在吡喃糖环的异头位置拥有一个氮原子，从而在异头位置产生正电荷而不是比在糖的环氧上。他们的合成，从容易获得的碳水化合物衍生物开始，包括 (i) 引入氨基官能团作为叠氮基，(ii) 形成具有还原胺化作用的 1-N-亚氨基吡喃糖环，以及 (iii) 立体选择性引入羟甲基或甲基，并以高度立体选择性和有效的方式完成。
• Heterocyclic compounds
  申请人：Novo Nordisk A/S

  公开号：US06046214A1

  公开（公告）日：2000-04-04

  Novel piperidine compounds are provided, and those compounds are useful in the treatment and/or prevention of diabetes, and especially non-insulin dependent diabetes (NIDDM or type 2 diabetes) including overnight or meal treatment and treatment or prevention of longterm complications, such as retinopathy, neuropathy, nephropathy, and micro- and macroangiopathy; treatment of hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis or myocardial ischemia.

  提供了新型哌啶化合物，这些化合物可用于治疗和/或预防糖尿病，特别是非胰岛素依赖性糖尿病（NIDDM或2型糖尿病），包括夜间或餐后治疗以及治疗或预防长期并发症，如视网膜病变、神经病变、肾病、微血管和宏血管病变；治疗高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化或心肌缺血。
• Iminosugars: potential inhibitors of liver glycogen phosphorylase
  作者：Palle Jakobsen、Jane M Lundbeck、Marit Kristiansen、Jens Breinholt、Helle Demuth、Jan Pawlas、Maria P Torres Candela、Birgitte Andersen、Niels Westergaard、Karsten Lundgren、Naoki Asano

  DOI：10.1016/s0968-0896(00)00291-1

  日期：2001.3

  The first synthesis of the single isomers (3R,4R,5R); (3S,4S,5S); (3R,4R,5S) and (3S,4S,5R) of 5-hydroxymethyl-piperidine-3,4-diol from Arecolin is reported, including the synthesis of a series of N-substituted derivatives of the (3R,4R,5R)-isomer (Isofagomine). The inhibitory effect of these isomers as well as of a series of N-substituted derivatives of the (3R,4R,SR)-isomer and selected hydroxypiperidine analogues on liver glycogen phosphorylase (GP) showed that the (3R,4R,5R) configuration was essential for obtaining an inhibitory effect at submicromolar concentration. The results also showed that all three hydroxy groups should be present and could not be substituted, nor were extra OH groups allowed if sub-micromolar inhibition should be obtained. Some inhibitory effect was retained for N-substituted derivatives of Isofagagomine; however, N-substitution always resulted in a loss of activity compared to the parent compound, IC50 values ranging from 1 to 100 muM were obtained for simple alkyl, arylalkyl and benzoylmethyl substituents. Furthermore, we found that it was not enough to assure inhibitory effect to have the (R,,R) configuration. Fagomine, the (2R,3R,4R)-2-hydroxymethylpiperidine-3,4-diol analogue, showed an IC50 value of 200 muM compared to 0.7 muM for Isofagomine. In addition, Isofagomine was able to prevent basal and glucagon stimulated glycogen degradation in cultured hepatocytes with IC50 values of 2-3 muM. (C) 2001 Elsevier Science Ltd. All rights reserved.
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：NOVO NORDISK A/S

  公开号：EP0983239A1

  公开（公告）日：2000-03-08
• TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES
  申请人：De Moor Olivier

  公开号：US20110237538A1

  公开（公告）日：2011-09-29

  Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.